Myeloid Therapeutics

Cell Therapy for Cancer

MT-302 Clin0 multiple cancers; MT-301 Clin0 liver cancer; Retrotransposon 2 efforts RD undisclosed

Myeloid Therapeutics is a clinical-stage immunology company developing a pipeline of next-generation mRNA-based immunotherapies. Their novel approach to cancer treatment harnesses the body's innate immune system, leveraging the natural anti-tumor properties of myeloid cells. Targeting the innate immune system offers a broader attack on cancer compared to therapies focused on the adaptive immune system. Because myeloid cells are readily available within the body, their use could reduce the need for complex cell manipulation techniques. Myeloid’s proprietary platform combines in vivo mRNA programming to target and activate myeloid cells and retrotransposon-mediated gene insertion technology to deliver larger genetic sequences than were previously possible.